ID   PAR16_HUMAN             Reviewed;         322 AA.
AC   Q8N5Y8; Q6PK64; Q9NX03;
DT   17-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   12-APR-2017, entry version 116.
DE   RecName: Full=Mono [ADP-ribose] polymerase PARP16 {ECO:0000305};
DE            EC=2.4.2.30 {ECO:0000269|PubMed:22701565};
DE   AltName: Full=ADP-ribosyltransferase diphtheria toxin-like 15 {ECO:0000303|PubMed:20106667};
DE   AltName: Full=Poly [ADP-ribose] polymerase 16;
DE            Short=PARP-16;
GN   Name=PARP16 {ECO:0000303|PubMed:20106667,
GN   ECO:0000312|HGNC:HGNC:26040};
GN   Synonyms=ARTD15 {ECO:0000303|PubMed:20106667},
GN   C15orf30 {ECO:0000312|HGNC:HGNC:26040};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Carcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   PRO-280.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NOMENCLATURE.
RX   PubMed=20106667; DOI=10.1016/j.tibs.2009.12.003;
RA   Hottiger M.O., Hassa P.O., Luscher B., Schuler H., Koch-Nolte F.;
RT   "Toward a unified nomenclature for mammalian ADP-
RT   ribosyltransferases.";
RL   Trends Biochem. Sci. 35:208-219(2010).
RN   [4]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF HIS-152 AND
RP   TYR-182.
RX   PubMed=23103912; DOI=10.1038/ncb2593;
RA   Jwa M., Chang P.;
RT   "PARP16 is a tail-anchored endoplasmic reticulum protein required for
RT   the PERK-and IRE1alpha-mediated unfolded protein response.";
RL   Nat. Cell Biol. 14:1223-1230(2012).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, INTERACTION WITH KPNB1,
RP   CATALYTIC ACTIVITY, MUTAGENESIS OF HIS-152 AND TYR-254,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND AUTO-ADP-RIBOSYLATION.
RX   PubMed=22701565; DOI=10.1371/journal.pone.0037352;
RA   Di Paola S., Micaroni M., Di Tullio G., Buccione R., Di Girolamo M.;
RT   "PARP16/ARTD15 is a novel endoplasmic-reticulum-associated mono-ADP-
RT   ribosyltransferase that interacts with, and modifies karyopherin-
RT   beta1.";
RL   PLoS ONE 7:E37352-E37352(2012).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 5-279 IN COMPLEX WITH NAD
RP   ANALOG, AUTO-ADP-RIBOSYLATION, DOMAIN PARP ALPHA-HELICAL, AND
RP   NAD-BINDING SITES.
RX   PubMed=22661712; DOI=10.1074/jbc.M112.379289;
RA   Karlberg T., Thorsell A.G., Kallas A., Schuler H.;
RT   "Crystal structure of human ADP-ribose transferase ARTD15/PARP16
RT   reveals a novel putative regulatory domain.";
RL   J. Biol. Chem. 287:24077-24081(2012).
CC   -!- FUNCTION: Intracellular mono-ADP-ribosyltransferase that may play
CC       a role in different processes through the mono-ADP-ribosylation of
CC       proteins involved in those processes (PubMed:23103912,
CC       PubMed:22701565). May play a role in the unfolded protein response
CC       (UPR), by ADP-ribosylating and activating EIF2AK3 and ERN1, two
CC       important UPR effectors (PubMed:23103912). May also mediate mono-
CC       ADP-ribosylation of karyopherin KPNB1 a nuclear import factor
CC       (PubMed:22701565). May not modify proteins on arginine, cysteine
CC       or glutamate residues compared to other mono-ADP-
CC       ribosyltransferases (PubMed:22701565).
CC       {ECO:0000269|PubMed:22701565, ECO:0000269|PubMed:23103912}.
CC   -!- CATALYTIC ACTIVITY: NAD(+) + (ADP-D-ribosyl)(n)-acceptor =
CC       nicotinamide + (ADP-D-ribosyl)(n+1)-acceptor.
CC       {ECO:0000269|PubMed:22701565}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=290 uM for NAD (at 37 degrees Celsius)
CC         {ECO:0000269|PubMed:22701565};
CC         Vmax=0.7 pmol/h/ug enzyme (at 37 degrees Celsius)
CC         {ECO:0000269|PubMed:22701565};
CC   -!- SUBUNIT: Interacts with KPNB1. {ECO:0000269|PubMed:22661712,
CC       ECO:0000269|PubMed:22701565}.
CC   -!- INTERACTION:
CC       Q53SE7:FLJ13057; NbExp=3; IntAct=EBI-10266912, EBI-10172181;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Single-pass
CC       type IV membrane protein {ECO:0000269|PubMed:22701565}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8N5Y8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8N5Y8-2; Sequence=VSP_020973;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q8N5Y8-3; Sequence=VSP_020974;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The N-terminal PARP alpha-helical domain is regulatory, it
CC       packs against the catalytic domain, and may relay effector-binding
CC       event to the NAD-binding site. {ECO:0000269|PubMed:22661712}.
CC   -!- PTM: Auto-ADP-ribosylated. {ECO:0000269|PubMed:22661712,
CC       ECO:0000269|PubMed:22701565}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK000516; BAA91222.1; -; mRNA.
DR   EMBL; BC006389; AAH06389.1; -; mRNA.
DR   EMBL; BC031074; AAH31074.1; -; mRNA.
DR   CCDS; CCDS10204.1; -. [Q8N5Y8-3]
DR   CCDS; CCDS81897.1; -. [Q8N5Y8-2]
DR   RefSeq; NP_001303872.1; NM_001316943.1. [Q8N5Y8-1]
DR   RefSeq; NP_001303873.1; NM_001316944.1. [Q8N5Y8-2]
DR   RefSeq; NP_060321.3; NM_017851.5. [Q8N5Y8-3]
DR   UniGene; Hs.30634; -.
DR   PDB; 4F0D; X-ray; 2.70 A; A/B=5-279.
DR   PDBsum; 4F0D; -.
DR   ProteinModelPortal; Q8N5Y8; -.
DR   SMR; Q8N5Y8; -.
DR   BioGrid; 120294; 26.
DR   IntAct; Q8N5Y8; 9.
DR   STRING; 9606.ENSP00000261888; -.
DR   iPTMnet; Q8N5Y8; -.
DR   PhosphoSitePlus; Q8N5Y8; -.
DR   BioMuta; PARP16; -.
DR   DMDM; 116248565; -.
DR   EPD; Q8N5Y8; -.
DR   MaxQB; Q8N5Y8; -.
DR   PaxDb; Q8N5Y8; -.
DR   PeptideAtlas; Q8N5Y8; -.
DR   PRIDE; Q8N5Y8; -.
DR   DNASU; 54956; -.
DR   Ensembl; ENST00000261888; ENSP00000261888; ENSG00000138617. [Q8N5Y8-3]
DR   Ensembl; ENST00000444347; ENSP00000396118; ENSG00000138617. [Q8N5Y8-2]
DR   GeneID; 54956; -.
DR   KEGG; hsa:54956; -.
DR   UCSC; uc002aop.4; human. [Q8N5Y8-1]
DR   CTD; 54956; -.
DR   GeneCards; PARP16; -.
DR   HGNC; HGNC:26040; PARP16.
DR   HPA; HPA017081; -.
DR   neXtProt; NX_Q8N5Y8; -.
DR   OpenTargets; ENSG00000138617; -.
DR   PharmGKB; PA134984504; -.
DR   eggNOG; ENOG410IF6E; Eukaryota.
DR   eggNOG; ENOG410ZP73; LUCA.
DR   GeneTree; ENSGT00390000014077; -.
DR   HOGENOM; HOG000253948; -.
DR   HOVERGEN; HBG058859; -.
DR   InParanoid; Q8N5Y8; -.
DR   KO; K00774; -.
DR   OMA; LHNGLHC; -.
DR   OrthoDB; EOG091G0E9B; -.
DR   PhylomeDB; Q8N5Y8; -.
DR   TreeFam; TF323413; -.
DR   BRENDA; 2.4.2.30; 2681.
DR   BRENDA; 2.4.2.31; 2681.
DR   Reactome; R-HSA-197264; Nicotinamide salvaging.
DR   GenomeRNAi; 54956; -.
DR   PRO; PR:Q8N5Y8; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000138617; -.
DR   CleanEx; HS_PARP16; -.
DR   ExpressionAtlas; Q8N5Y8; baseline and differential.
DR   Genevisible; Q8N5Y8; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IMP:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0071782; C:endoplasmic reticulum tubular network; IMP:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB.
DR   GO; GO:0019900; F:kinase binding; IPI:UniProtKB.
DR   GO; GO:0003950; F:NAD+ ADP-ribosyltransferase activity; IMP:UniProtKB.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IMP:UniProtKB.
DR   GO; GO:0006987; P:activation of signaling protein activity involved in unfolded protein response; IMP:UniProtKB.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IMP:UniProtKB.
DR   GO; GO:0034356; P:NAD biosynthesis via nicotinamide riboside salvage pathway; TAS:Reactome.
DR   GO; GO:0060548; P:negative regulation of cell death; IMP:UniProtKB.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IMP:UniProtKB.
DR   GO; GO:0006471; P:protein ADP-ribosylation; IMP:UniProtKB.
DR   GO; GO:0070213; P:protein auto-ADP-ribosylation; IMP:UniProtKB.
DR   InterPro; IPR012317; Poly(ADP-ribose)pol_cat_dom.
DR   Pfam; PF00644; PARP; 1.
DR   PROSITE; PS51059; PARP_CATALYTIC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Alternative splicing;
KW   Complete proteome; Endoplasmic reticulum; Glycosyltransferase;
KW   Membrane; NAD; Polymorphism; Reference proteome; Transferase;
KW   Transmembrane; Transmembrane helix; Unfolded protein response.
FT   CHAIN         1    322       Mono [ADP-ribose] polymerase PARP16.
FT                                /FTId=PRO_0000252437.
FT   TOPO_DOM      1    287       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    288    308       Helical. {ECO:0000255}.
FT   TOPO_DOM    309    322       Lumenal. {ECO:0000255}.
FT   DOMAIN        5     91       PARP alpha-helical.
FT   DOMAIN       94    279       PARP catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00397}.
FT   COMPBIAS    297    303       Poly-Leu.
FT   BINDING     152    152       NAD. {ECO:0000269|PubMed:22661712}.
FT   BINDING     182    182       NAD. {ECO:0000269|PubMed:22661712}.
FT   BINDING     254    254       NAD; may stabilize a reaction
FT                                intermediate.
FT                                {ECO:0000269|PubMed:22661712}.
FT   SITE        193    193       Nicotinamide-stacking aromate.
FT                                {ECO:0000269|PubMed:22661712}.
FT   VAR_SEQ      59    173       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_020973.
FT   VAR_SEQ     277    277       K -> KS (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_020974.
FT   VARIANT     280    280       S -> P (in dbSNP:rs17852901).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_027864.
FT   MUTAGEN     152    152       H->A: Loss of ADP-ribosyltransferase
FT                                activity; when associated with A-254.
FT                                {ECO:0000269|PubMed:22701565}.
FT   MUTAGEN     152    152       H->Q: ADP-ribosyltransferase activity is
FT                                only 6% of wild-type; when associated
FT                                with A-182.
FT                                {ECO:0000269|PubMed:23103912}.
FT   MUTAGEN     182    182       Y->A: ADP-ribosyltransferase activity is
FT                                only 6% of wild-type; when associated
FT                                with Q-152.
FT                                {ECO:0000269|PubMed:23103912}.
FT   MUTAGEN     254    254       Y->A: Loss of ADP-ribosyltransferase
FT                                activity; when associated with H-152.
FT                                {ECO:0000269|PubMed:22701565}.
FT   HELIX         6     15       {ECO:0000244|PDB:4F0D}.
FT   HELIX        17     32       {ECO:0000244|PDB:4F0D}.
FT   HELIX        36     39       {ECO:0000244|PDB:4F0D}.
FT   HELIX        45     47       {ECO:0000244|PDB:4F0D}.
FT   STRAND       48     51       {ECO:0000244|PDB:4F0D}.
FT   HELIX        55     63       {ECO:0000244|PDB:4F0D}.
FT   HELIX        68     72       {ECO:0000244|PDB:4F0D}.
FT   HELIX        80     89       {ECO:0000244|PDB:4F0D}.
FT   STRAND       93     99       {ECO:0000244|PDB:4F0D}.
FT   HELIX       103    111       {ECO:0000244|PDB:4F0D}.
FT   STRAND      123    130       {ECO:0000244|PDB:4F0D}.
FT   HELIX       134    142       {ECO:0000244|PDB:4F0D}.
FT   STRAND      147    153       {ECO:0000244|PDB:4F0D}.
FT   HELIX       156    158       {ECO:0000244|PDB:4F0D}.
FT   HELIX       159    165       {ECO:0000244|PDB:4F0D}.
FT   STRAND      176    178       {ECO:0000244|PDB:4F0D}.
FT   STRAND      181    185       {ECO:0000244|PDB:4F0D}.
FT   HELIX       187    191       {ECO:0000244|PDB:4F0D}.
FT   STRAND      207    218       {ECO:0000244|PDB:4F0D}.
FT   STRAND      255    257       {ECO:0000244|PDB:4F0D}.
FT   HELIX       260    262       {ECO:0000244|PDB:4F0D}.
FT   STRAND      263    272       {ECO:0000244|PDB:4F0D}.
SQ   SEQUENCE   322 AA;  36383 MW;  DA1C99E8A1305982 CRC64;
     MQPSGWAAAR EAAGRDMLAA DLRCSLFASA LQSYKRDSVL RPFPASYARG DCKDFEALLA
     DASKLPNLKE LLQSSGDNHK RAWDLVSWIL SSKVLTIHSA GKAEFEKIQK LTGAPHTPVP
     APDFLFEIEY FDPANAKFYE TKGERDLIYA FHGSRLENFH SIIHNGLHCH LNKTSLFGEG
     TYLTSDLSLA LIYSPHGHGW QHSLLGPILS CVAVCEVIDH PDVKCQTKKK DSKEIDRRRA
     RIKHSEGGDI PPKYFVVTNN QLLRVKYLLV YSQKPPKRAS SQLSWFSSHW FTVMISLYLL
     LLLIVSVINS SAFQHFWNRA KR
//
